Mixed results for pharma sector

Ranbaxy's profits beat expectations, Biocon's shot in the arm came from a plan to list its subsidiary Syngene. The revenues of Ranbaxy grew by 5.7 per cent to about Rs 1,800 crore for the fourth quarter ended December 31.

Related Videos